320 related articles for article (PubMed ID: 18799369)
1. 6-Thioguanine therapy in Crohn's disease--observational data in Swedish patients.
Almer SH; Hjortswang H; Hindorf U
Dig Liver Dis; 2009 Mar; 41(3):194-200. PubMed ID: 18799369
[TBL] [Abstract][Full Text] [Related]
2. Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.
Dubinsky MC; Feldman EJ; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2003 May; 98(5):1058-63. PubMed ID: 12809828
[TBL] [Abstract][Full Text] [Related]
3. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Goldenberg BA; Rawsthorne P; Bernstein CN
Am J Gastroenterol; 2004 Sep; 99(9):1744-8. PubMed ID: 15330913
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease.
Qasim A; McDonald S; Sebastian S; McLoughlin R; Buckley M; O'Connor H; O'Morain C
Scand J Gastroenterol; 2007 Feb; 42(2):194-9. PubMed ID: 17327939
[TBL] [Abstract][Full Text] [Related]
5. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease.
Andoh A; Tsujikawa T; Ban H; Hashimoto T; Bamba S; Ogawa A; Sasaki M; Saito Y; Fujiyama Y
J Gastroenterol Hepatol; 2008 Sep; 23(9):1373-7. PubMed ID: 18662197
[TBL] [Abstract][Full Text] [Related]
6. 6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprine.
Roblin X; Serre-Debeauvais F; Phelip JM; Faucheron JL; Hardy G; Chartier A; Helluwaert F; Bessard G; Bonaz B
Aliment Pharmacol Ther; 2005 Apr; 21(7):829-39. PubMed ID: 15801918
[TBL] [Abstract][Full Text] [Related]
7. Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
Herrlinger KR; Fellermann K; Fischer C; Kreisel W; Deibert P; Schoelmerich J; Fleig WE; Ruhl A; Reinshagen M; Greinwald R; Stange EF; Schwab M
Aliment Pharmacol Ther; 2004 Jun; 19(12):1269-76. PubMed ID: 15191508
[TBL] [Abstract][Full Text] [Related]
8. A 6-thioguanine nucleotide threshold level of 400 pmol/8 x 10(8) erythrocytes predicts azathioprine refractoriness in patients with inflammatory bowel disease and normal TPMT activity.
Roblin X; Peyrin-Biroulet L; Phelip JM; Nancey S; Flourie B
Am J Gastroenterol; 2008 Dec; 103(12):3115-22. PubMed ID: 19086961
[TBL] [Abstract][Full Text] [Related]
9. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine.
Bonaz B; Boitard J; Marteau P; Lémann M; Coffin B; Flourié B; Belaiche J; Cadiot G; Metman EH; Cortot A; Colombel JF;
Aliment Pharmacol Ther; 2003 Aug; 18(4):401-8. PubMed ID: 12940925
[TBL] [Abstract][Full Text] [Related]
10. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
Navarro FA; Hanauer SB; Kirschner BS
J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
[TBL] [Abstract][Full Text] [Related]
11. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery.
Papay P; Reinisch W; Ho E; Gratzer C; Lissner D; Herkner H; Riss S; Dejaco C; Miehsler W; Vogelsang H; Novacek G
Am J Gastroenterol; 2010 May; 105(5):1158-64. PubMed ID: 20010925
[TBL] [Abstract][Full Text] [Related]
12. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP; Luna M; Maté J; González-Guijarro L; Cara C; Pajares JM
Hepatogastroenterology; 2006; 53(69):399-404. PubMed ID: 16795981
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Lees CW; Maan AK; Hansoti B; Satsangi J; Arnott ID
Aliment Pharmacol Ther; 2008 Feb; 27(3):220-7. PubMed ID: 17988235
[TBL] [Abstract][Full Text] [Related]
14. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study.
Chebli JM; Gaburri PD; De Souza AF; Pinto AL; Chebli LA; Felga GE; Forn CG; Pimentel CF
J Gastroenterol Hepatol; 2007 Feb; 22(2):268-74. PubMed ID: 17295882
[TBL] [Abstract][Full Text] [Related]
15. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.
Weiss B; Lerner A; Shapiro R; Broide E; Levine A; Fradkin A; Bujanover Y
J Pediatr Gastroenterol Nutr; 2009 May; 48(5):526-30. PubMed ID: 19412004
[TBL] [Abstract][Full Text] [Related]
16. Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Kwan LY; Devlin SM; Mirocha JM; Papadakis KA
Dig Liver Dis; 2008 Jun; 40(6):425-32. PubMed ID: 18304898
[TBL] [Abstract][Full Text] [Related]
17. Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
López-Martín C; Chaparro M; Espinosa L; Bejerano A; Maté J; Gisbert JP
Gastroenterol Hepatol; 2011; 34(6):385-92. PubMed ID: 21616565
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of methotrexate in Crohn's disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine.
Wahed M; Louis-Auguste JR; Baxter LM; Limdi JK; McCartney SA; Lindsay JO; Bloom SL
Aliment Pharmacol Ther; 2009 Sep; 30(6):614-20. PubMed ID: 19552632
[TBL] [Abstract][Full Text] [Related]
19. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.
Dubinsky MC; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
Inflamm Bowel Dis; 2001 Aug; 7(3):181-9. PubMed ID: 11515842
[TBL] [Abstract][Full Text] [Related]
20. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis.
Hibi T; Naganuma M; Kitahora T; Kinjyo F; Shimoyama T
J Gastroenterol; 2003; 38(8):740-6. PubMed ID: 14505127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
